- Pemetrexed
-
- $1.00 / 1kg
-
2024-05-29
- CAS:137281-23-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 200
- Pemetrexed
-
- $0.00 / 10mg
-
2024-04-10
- CAS:137281-23-3
- Min. Order: 10mg
- Purity: 90%+
- Supply Ability: 10g
- Pemetrexed Disodium
-
- $200.00 / 1kg
-
2023-06-26
- CAS:137281-23-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg/Month
|
| | Pemetrexed Basic information |
| Product Name: | Pemetrexed | | Synonyms: | PeMetrexed-13C5;PeMetrexed-15C5;N-[4-[2-(2-aMino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyriMidin-5-yl)ethyl]benzoyl]L-GlutaMic acid (PeMetrexed acid);N-[4-[2-(2-AMino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyriMidin-5-yl)ethyl]benzoyl]-L-glutaMic acid;(S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedi;N-[4-[2-(2-Amino-4,7;(2R)-2-{[4-(2-{2-aMino-4-oxo-1H,4H,7H-pyrrolo[2,3-d]pyriMidin-5-yl}ethyl)phenyl]forMaMido}pentanedioic acid;N-(4- 2-(2-AMino-4,7-Dihydro-4-oxo-1H-pyrrol... | | CAS: | 137281-23-3 | | MF: | C20H21N5O6 | | MW: | 427.41 | | EINECS: | 680-625-9 | | Product Categories: | Anti-cancer & immunity;API;CIALIS | | Mol File: | 137281-23-3.mol |  |
| | Pemetrexed Chemical Properties |
| density | 1.59±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | solubility | slightly sol. in Methanol | | form | powder to crystal | | pka | 3.58±0.10(Predicted) | | color | White to Blue | | Merck | 14,7077 | | CAS DataBase Reference | 137281-23-3(CAS DataBase Reference) |
| | Pemetrexed Usage And Synthesis |
| Chemical Properties | N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt is Off-White Solid | | Uses | Pemetrexed is used in the treatment of malignant pleural mesothelioma (MPM) and erectile dysfunction therapy. | | Definition | ChEBI: Pemetrexed is an N-acylglutamic acid in which the N-acyl group is specified as 4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). It has a role as an antineoplastic agent, an antimetabolite, an EC 2.1.1.45 (thymidylate synthase) inhibitor, an EC 1.5.1.3 (dihydrofolate reductase) inhibitor and an EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor. It is a pyrrolopyrimidine and a N-acyl-L-glutamic acid. It is a conjugate acid of a pemetrexed(2-). | | Brand name | Alimta (Lilly). | | Side effects | The most common side effects for pemetrexed include fatigue, nausea, vomiting, anorexia, mucositis, myelosuppression ± infection, bleeding, rash, diarrhea and ↑ LFTs.
Severe myelosuppression is often dose-limiting for pemetrexed. Sepsis, in some cases fatal, have occurred in approximately 1% of patients in clinical trials. Prophylactic folic acid and intramuscular vitamin B12 supplements are necessary to reduce hematologic or non-hematologic toxicities.
Pemetrexed may cause serious and in some cases fatal dermatologic toxicities. Rarely, StevensJohnson syndrome and toxic epidermal necrolysis have been reported. | | storage | Store at +4°C | | Mode of action | Pemetrexed is a pyrrolopyrimidine antifolate that exerts its antineoplastic activity by inhibiting thymidylate synthase (TS), glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), which are involved in folate metabolism and DNA synthesis, resulting in inhibition of purine and thymidine nucleotide synthesis. |
| | Pemetrexed Preparation Products And Raw materials |
|